CPRI
Capri Holdings Limited
CPRI has the edge over LCID overall, supported by lower modeled downside and stronger valuation.
LCID
Lucid Group, Inc.
LCID offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
CPRI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
CPRI's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CPRI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8x | $14.12 | -31% |
| Forward | 9.4x | $20.38 | — |
| Current | 12x | $20.38 | — |
| Fair | 13x | $23.01 | +13% |
| Expensive | 21x | $36.91 | +81% |
Historical ranges are pointers, not guarantees.
CPRI's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 9.4x next year's earnings, in its cheap range.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CPRI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect CPRI's earnings to grow and its profitability to improve, with its revenue holding steady.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CPRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.17 | +23% |
| Q3 2026 | $1.77 | +$11.64 |
| Q2 2026 | $1.30 | +$10.75 |
| Q1 2026 | $1.14 | +$11.14 |
| Q4 2025 | -$4.30 | +$4.24 |
| Q3 2025 | -$9.87 | -$6.82 |
| Q2 2025 | -$9.45 | -$6.97 |
| Q1 2025 | -$10.00 | -$8.04 |
| Q4 2024 | -$8.54 | -547% |
CPRI has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
CPRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $809M | -5.5% |
| Q2 2026 | $769M | -3.5% |
| Q1 2026 | $796M | -23% |
| Q4 2025 | $1B | -19% |
| Q3 2025 | $856M | -21% |
| Q2 2025 | $797M | -25% |
| Q1 2025 | $1B | -15% |
| Q4 2024 | $1.3B | -12% |
CPRI's revenue has slid since its 2021 peak: $809M last quarter, down 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.2% | +2.6 points |
| Q2 2026 | 2.2% | +0.2 points |
| Q1 2026 | -3.4% | +7.8 points |
| Q4 2025 | 4.5% | +51 points |
| Q3 2025 | -1.4% | +2.1 points |
| Q2 2025 | 2% | +2.8 points |
| Q1 2025 | -11% | +33 points |
| Q4 2024 | -47% | -55 points |
CPRI has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over CPRI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CPRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $36M | +$101M |
| Q2 2026 | $48M | +$69M |
| Q1 2026 | -$83M | +$105M |
| Q4 2025 | $183M | -34% |
| Q3 2025 | -$65M | -383% |
| Q2 2025 | -$21M | -153% |
| Q1 2025 | -$188M | -$182M |
| Q4 2024 | $278M | -11% |
CPRI has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CPRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.9% | -5.7M shares |
| 1 year | -7.9% | -9.4M shares |
| 3 years | -6.1% | -7.2M shares |
| 5 years | -28% | -43.9M shares |
| Available history | -27% | -41.8M shares |
CPRI has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $150M |
| Q2 2026 | $54M |
| Q1 2026 | $79M |
| Q4 2025 | — |
| Q3 2025 | $1M |
| Q2 2025 | $1M |
| Q1 2025 | — |
| Q4 2024 | — |
CPRI spent $283M buying back its own shares over the past year, more than ten times what it spent the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CPRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 1.6x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q4 2023 | 3.9x | Elevated |
| Q3 2023 | 3.6x | Elevated |
| Q2 2023 | 2.5x | Moderate |
| Q1 2023 | 1.9x | Healthy |
CPRI's net debt is about 2.1 years of its operating earnings (EBITDA), down from 3.9 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CPRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.5 | Neutral |
| Stochastic | 88.5 | Overbought |
CPRI's weekly RSI is 64 (neutral) and its Stochastic is 88 (overbought).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CPRI PE vs Consumer Cyclical Sector
| Metric | CPRI | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 18x | 36% below |
| PE % | 43 | 47 | 4 pts below |
CPRI is trading at 12x earnings, a 36% discount to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CPRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.0 | 20% above |
| 20 week MA | $16.0 | 27% above |
| 50 week MA | $19.1 | 6.9% above |
| 100 week MA | $19.5 | 4.5% above |
| 200 week MA | $30.6 | 33% below |
CPRI has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CPRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.5 | $42.4 | +13% |
| 2021 | $42.4 | $61.7 | +45% |
| 2022 | $61.7 | $55.7 | -9.7% |
| 2023 | $55.7 | $50.2 | -9.8% |
| 2024 | $50.2 | $21.0 | -58% |
| 2025 | $21.0 | $25.0 | +19% |
| 2026 YTD | $25.0 | $20.4 | -18% |
CPRI has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.